Sequence 17 from Patent US 20110159022

General Information


DRACP ID  DRACP01325

Peptide Name   Sequence 17 from Patent US 20110159022

Sequence  AQTQRIRCRV

Sequence Length  10

UniProt ID  P21741  A5DCV3  B5Z8L0  Q1CS51  O25812  Q9ZK11  Q17VM4 

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01325

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C49H91N21O14S

Absent amino acids  DEFGHKLMNPSWY

Common amino acids  R

Mass  139117

Pl  12.2

Basic residues  3

Acidic residues  0

Hydrophobic residues  3

Net charge  3

Boman Index  -4636

Hydrophobicity  -82

Aliphatic Index  78

Half Life 
  Mammalian: 4.4 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2011/0159022 A1

Patent Title  Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.

Other Iinformation  Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status: Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;

Other Published ID  CA2728459A1  CN102123731A  EP2296697A1  WO2009153463A1 




DRACP is developed by Dr.Zheng's team.